Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Viking Therapeutics VKTX Stock Holding History

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-267,464	Closed	-$10.8M	–	60
2024 Q4	$10.8M	Sell	267,464 -226,486	-46%	-$12.9M	1.3%	30
2024 Q3	$31.3M	Sell	493,950 -26,125	-5%	-$1.53M	4.34%	4
2024 Q2	$27.6M	Buy	520,075 +5,382	+1%	+$353K	4.48%	6
2024 Q1	$42.2M	Buy	+514,693	New	+$22.9M	6.51%	3

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's VKTX Position: Q1 2025 in Review

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 267,464 shares — an estimated $10.8M sold.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in VKTX in Q1 2024 and held it in 4 quarters. The position peaked at $42.2M in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold 267,464 Viking Therapeutics shares in Q1 2025, an estimated $10.8M.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in Viking Therapeutics in Q1 2024 and held it in 4 quarters.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's Viking Therapeutics position peaked at $42.2M in Q1 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's 13F filing for Q1 2025, filed 6 May 2025.